Hospital Universitario Germans Trias i Pujol
Hospital Universitario Germans Trias i Pujol
Carretera del Canyet, s/n 08916 Badalona
Select an option
I am a doctor
I am a sponsor
Our team
Medical staff
Sílvia Roure Díez
Open studies
Esophageal cancer
A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal Cancers - HERIZON-GEA-01 - Zymeworks Inc.See more
Trastuzumab Deruxtecan for Subjects With HER2-Positive Gastric Cancer or Gastro-Esophageal Junction Adenocarcinoma After Progression on or After a Trastuzumab-Containing Regimen (DESTINY-Gastric04) - DESTINY-Gastric04 - AstraZenecaSee more
Gastric cancer
A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal Cancers - HERIZON-GEA-01 - Zymeworks Inc.See more
Trastuzumab Deruxtecan for Subjects With HER2-Positive Gastric Cancer or Gastro-Esophageal Junction Adenocarcinoma After Progression on or After a Trastuzumab-Containing Regimen (DESTINY-Gastric04) - DESTINY-Gastric04 - AstraZenecaSee more
Gastroesophageal cancer
A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal Cancers - HERIZON-GEA-01 - Zymeworks Inc.See more
Trastuzumab Deruxtecan for Subjects With HER2-Positive Gastric Cancer or Gastro-Esophageal Junction Adenocarcinoma After Progression on or After a Trastuzumab-Containing Regimen (DESTINY-Gastric04) - DESTINY-Gastric04 - AstraZenecaSee more
Breast Cancer
A Study Evaluating the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for Participants With HER2-Positive Breast Cancer at High Risk of Recurrence Following Preoperative Therapy - Astefania - Hoffmann-La RocheSee more
